<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37555926</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Characterizing long-COVID brain fog: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>4640</StartPage><EndPage>4646</EndPage><MedlinePgn>4640-4646</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11913-w</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Long COVID or post-COVID condition (PCC) is a common complication following acute COVID-19 infection. PCC is a multi-systems disease with neurocognitive impairment frequently reported regardless of age. Little is known about the risk factors, associated biomarkers and clinical trajectory of patients with this symptom.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine differences in clinical risk factors, associated biochemical markers and longitudinal clinical trajectories between patients with PCC with subjective neurocognitive symptoms (NC+) or without (NC-).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A retrospective longitudinal cohort study was performed using a well-characterized provincial database of patients with clinically confirmed PCC separated into NC+&#x2009;and NC- cohorts. Demographical, clinical and biochemical differences at initial consultation between the two patient cohorts were analyzed in cross-section. Multivariate regression analyses were conducted to identify independent risk factors for neurocognitive impairment. Determination of the recovery trajectory was performed using serial assessments of the patient-reported health-related quality of life (HR-QoL) metric Eq-5D-5L-vas score.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Women, milder acute infection and pre-existing mental health diagnoses were independently associated with subjective neurocognitive impairment at 8&#xa0;months post-infection. NC&#x2009;+&#x2009;patients demonstrated lower levels of IgG, IgG1 and IgG3 compared to NC- patients. The NC&#x2009;+&#x2009;cohort had poorer HR-QoL at initial consultation 8&#xa0;months post-infection with gradual improvement over 20&#xa0;months post-infection.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neurocognitive impairment represents a severe phenotype of PCC, associated with unique risk factors, aberrancy in immune response and a delayed recovery trajectory. Those with risk factors for neurocognitive impairment can be identified early in the disease trajectory for more intense medical follow-up.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Grace Y</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0002-7366-193X</Identifier><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, University of Alberta and Alberta Health Services, 3-111C Clinical Sciences Building, 11302 83 Ave NW, Edmonton, AB, T6G 2G3, Canada. glam@ualberta.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada. glam@ualberta.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damant</LastName><ForeName>Ronald W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, University of Alberta and Alberta Health Services, 3-111C Clinical Sciences Building, 11302 83 Ave NW, Edmonton, AB, T6G 2G3, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrara</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, University of Alberta and Alberta Health Services, 3-111C Clinical Sciences Building, 11302 83 Ave NW, Edmonton, AB, T6G 2G3, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Rachel K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>Division of Respiratory Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stickland</LastName><ForeName>Michael K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, University of Alberta and Alberta Health Services, 3-111C Clinical Sciences Building, 11302 83 Ave NW, Edmonton, AB, T6G 2G3, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogando</LastName><ForeName>Natacha S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Alberta and Alberta Health Services, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Power</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, University of Alberta and Alberta Health Services, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Maeve P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Division of Pulmonary Medicine, Department of Medicine, University of Alberta and Alberta Health Services, 3-111C Clinical Sciences Building, 11302 83 Ave NW, Edmonton, AB, T6G 2G3, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alberta Respiratory Centre, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neurocognitive impairment</Keyword><Keyword MajorTopicYN="N">Post-COVID condition</Keyword><Keyword MajorTopicYN="N">Recovery trajectory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>12</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>9</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37555926</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11913-w</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11913-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kayaaslan B et al (2021) Post-COVID syndrome: a single-center questionnaire study on 1007 participants recovered from COVID-19. J Med Virol. https://doi.org/10.1002/jmv.27198</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27198</ArticleId><ArticleId IdType="pubmed">34255355</ArticleId><ArticleId IdType="pmc">8426910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolston VS et al (2018) The influence of hormonal fluctuation on inflammatory bowel disease symptom severity&#x2014;a cross-sectional cohort study. Inflamm Bowel Dis 24:387&#x2013;393</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ibd/izx004</ArticleId><ArticleId IdType="pubmed">29361085</ArticleId><ArticleId IdType="pmc">6196767</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaibi H, Touil A, Fessi R, Ben Amar J, Aouina H (2020) Asthma in menopausal women: clinical and functional particularities. Tanaffos 19:216&#x2013;222</Citation><ArticleIdList><ArticleId IdType="pubmed">33815542</ArticleId><ArticleId IdType="pmc">8008417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A et al (2021) Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine 39:101044. https://doi.org/10.1016/j.eclinm.2021.101044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId><ArticleId IdType="pmc">8298139</ArticleId></ArticleIdList></Reference><Reference><Citation>Blazhenets G et al (2021) Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J Nucl Med 62:910&#x2013;915</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.262128</ArticleId><ArticleId IdType="pubmed">33789937</ArticleId><ArticleId IdType="pmc">8882885</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ (2023) Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 21:133&#x2013;146</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE et al (2021) Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pubmed">34765955</ArticleId><ArticleId IdType="pmc">8573152</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M et al (2022) Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry 9:815&#x2013;827</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId><ArticleId IdType="pmc">9385200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall PA et al (2023) Neurocognitive and psychiatric symptoms following infection with COVID-19: evidence from laboratory and population studies. Brain Behav Immunity Health 28:100595</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2023.100595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall PA et al (2022) Cognitive function following SARS-CoV-2 infection in a population-representative Canadian sample. Brain Behav Immunity Health 21:100454</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100454</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawilska JB, Kuczy&#x144;ska K (2022) Psychiatric and neurological complications of long COVID. J Psychiatr Res 156:349&#x2013;360</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.10.045</ArticleId><ArticleId IdType="pubmed">36326545</ArticleId><ArticleId IdType="pmc">9582925</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein SR et al (2022) SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612:758&#x2013;763. https://doi.org/10.1038/s41586-022-05542-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId><ArticleId IdType="pmc">9749650</ArticleId></ArticleIdList></Reference><Reference><Citation>Roczkowsky A et al. COVID-19 induces neuroinflammation and suppresses peroxisomes in the brain. Ann Neurol</Citation></Reference><Reference><Citation>Spudich S, Nath A (2022) Nervous system consequences of COVID-19. Science 375:267&#x2013;269</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Y-J et al (2023) Biomarkers in long COVID-19: a systematic review. Front Med. https://doi.org/10.3389/fmed.2023.1085988</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1085988</ArticleId><ArticleId IdType="pubmed">37434066</ArticleId><ArticleId IdType="pmc">9898702</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y et al (2022) Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. https://doi.org/10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pubmed">36347254</ArticleId><ArticleId IdType="pmc">9942426</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M et al (2021) Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Regional Health Europe 6:100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId><ArticleId IdType="pmc">8129613</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C et al (2022) Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun 13:446</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId><ArticleId IdType="pmc">8789854</ArticleId></ArticleIdList></Reference><Reference><Citation>Esp&#xed;n E et al (2023) Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine 91:104552</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104552</ArticleId><ArticleId IdType="pubmed">37037165</ArticleId><ArticleId IdType="pmc">10082390</ArticleId></ArticleIdList></Reference><Reference><Citation>Son K et al (2023) Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur Respir J 61:2200970</Citation><ArticleIdList><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n J et al (2022) Immunologic phenotype of patients with long-COVID syndrome of 1-year duration. Front Immunol 13:920627</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.920627</ArticleId><ArticleId IdType="pubmed">36090973</ArticleId><ArticleId IdType="pmc">9451924</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ et al (2022) Plasma markers of neurologic injury and inflammation in people with self-reported neurologic postacute sequelae of SARS-CoV-2 infection. Neurol Neuroimmunol Neuroinflamm 9:e200003</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000200003</ArticleId><ArticleId IdType="pubmed">35701186</ArticleId><ArticleId IdType="pmc">9210548</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdy R et al (2022) Characteristics and risk factors of persistent neuropathic pain in recovered COVID-19 patients. Pain Med 23:774&#x2013;781</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnab341</ArticleId><ArticleId IdType="pubmed">34931670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique L et al (2022) Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: a longitudinal observational study. medRxiv. https://doi.org/10.1101/2022.06.07.22276020</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.07.22276020</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, Scheltens P (2005) Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 76:v2&#x2013;v7</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.082867</ArticleId><ArticleId IdType="pubmed">16291918</ArticleId><ArticleId IdType="pmc">1765715</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid JC et al (2021) Functional recovery following hospitalisation of patients diagnosed with COVID-19: a protocol for a longitudinal cohort study. BMJ Open 11:e053021</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-053021</ArticleId><ArticleId IdType="pubmed">34903545</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C et al (2021) 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England) 397:220&#x2013;232</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L et al (2022) Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil 101:48</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001910</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>Giurgi-Oncu C et al (2021) Cardiovascular abnormalities and mental health difficulties result in a reduced quality of life in the post-acute COVID-19 syndrome. Brain Sci 11:1456</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci11111456</ArticleId><ArticleId IdType="pubmed">34827455</ArticleId><ArticleId IdType="pmc">8615893</ArticleId></ArticleIdList></Reference><Reference><Citation>Team TA (2018) Alberta Population Norms for Eq5D-5L. https://apersu.ca/wp-content/uploads/2020/10/Alberta-Norms-Report_APERSU-1.pdf</Citation></Reference><Reference><Citation>Premraj L et al (2022) Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci 434:120162</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId><ArticleId IdType="pmc">8798975</ArticleId></ArticleIdList></Reference><Reference><Citation>Iosifescu AL, Hoogenboom WS, Buczek AJ, Fleysher R, Duong TQ (2022) New-onset and persistent neurological and psychiatric sequelae of COVID-19 compared to influenza: a retrospective cohort study in a large New York City healthcare network. Int J Methods Psychiatr Res 31:e1914</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mpr.1914</ArticleId><ArticleId IdType="pubmed">35706352</ArticleId><ArticleId IdType="pmc">9349863</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer PT, Hellwig S, Blazhenets G, Hosp JA (2022) Molecular imaging findings on acute and long-term effects of COVID-19 on the brain: a systematic review. J Nucl Med 63:971&#x2013;980</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.121.263085</ArticleId><ArticleId IdType="pubmed">35177424</ArticleId><ArticleId IdType="pmc">9258567</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson JS, Thornton AC, Ainger T, Garvy BA (2023) Long-term high-dose immunoglobulin successfully treats long COVID patients with pulmonary, neurologic, and cardiologic symptoms. Front Immunol 13:1033651</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1033651</ArticleId><ArticleId IdType="pubmed">36818469</ArticleId><ArticleId IdType="pmc">9932260</ArticleId></ArticleIdList></Reference><Reference><Citation>Oaklander AL et al (2022) Peripheral neuropathy evaluations of patients with prolonged long COVID. Neurol Neuroimmunol Neuroinflamm 9:e1146</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000001146</ArticleId><ArticleId IdType="pubmed">35232750</ArticleId><ArticleId IdType="pmc">8889896</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganotti P, Garascia G, Furlanis G, Buoite Stella A (2023) Efficacy of intravenous immunoglobulin (IVIg) on COVID-19-related neurological disorders over the last 2 years: an up-to-date narrative review. Front Neurosci. https://doi.org/10.3389/fnins.2023.1159929</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1159929</ArticleId><ArticleId IdType="pubmed">37179564</ArticleId><ArticleId IdType="pmc">10166837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlgren C et al (2023) Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study. Lancet Reg Health Eur 28:100595</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100595</ArticleId><ArticleId IdType="pubmed">36855599</ArticleId><ArticleId IdType="pmc">9951394</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones R et al (2021) Risk predictors and symptom features of long COVID within a broad primary care patient population including both tested and untested patients. Pragmatic Observ Res 12:93&#x2013;104</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/POR.S316186</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinkmann F et al. (2021) Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection. Eur Respir J</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>